Search results for "Anemia"

showing 10 items of 352 documents

Factors involved in gastrointestinal bleeding in advanced cancer patients followed at home

2003

Abstract There is a lack of information on the frequency of symptomatic gastrointestinal bleeding in patients with advanced cancer. This group of patients presents several risk factors for developing gastrointestinal bleeding. The aim of this multicenter longitudinal survey was to assess the frequency of gastrointestinal bleeding and possible factors implicated in advanced cancer patients followed at home. A consecutive sample of 439 patients who referred to home palliative care program entered the study. Age, gender, primary cancer and known metastases, possible associated pathologies, history of peptic disease, use of previous or actual nonsteroidal anti-inflammatory drugs (NSAIDs) and st…

Malemedicine.medical_specialtyGastrointestinal bleedingPalliative careBlood transfusionAnemiamedicine.medical_treatmentgastrointestinal bleedingSettore MED/42 - Igiene Generale E ApplicataGastroenterologyadvanced cancer patientGastrointestinal AgentsRisk FactorsMelenaNeoplasmsInternal medicinemedicineHumansLongitudinal StudiesProspective StudiesProspective cohort studybusiness.industryAnti-Inflammatory Agents Non-SteroidalPalliative CareCancermedicine.diseaseHome Care ServicesAdvanced cancerhome palliative careOncologyFemaleSteroidsmedicine.symptomGastrointestinal HemorrhagebusinessFollow-Up StudiesSupportive Care in Cancer
researchProduct

ITPA deficiency and ribavirin level are still predictive of anaemia in HCV–HIV-coinfected patients receiving ribavirin combined with a first-generati…

2017

Background We aimed to determine the impact of inosine triphosphatase (ITPA) deficiency on ribavirin (RBV)-induced anaemia in HIV–HCV-coinfected patients receiving a triple therapy including the haematotoxic direct-acting antiviral agent boceprevir (BOC). Methods Patients of the ANRS HC27 BocepreVIH study were genotyped for two ITPA single nucleotide polymorphisms involved in ITPA deficiency. RBV trough concentration (Ctrough) was determined at week (W)4 and W8. Impact of ITPA deficiency on anaemia, RBV Ctrough, response and haematotoxicity (grade 3/4 anaemia, erythropoietin [EPO] use, RBV dose reduction or transfusion between day [D]0 and W8) was evaluated. Impact of RBV Ctrough on anaemia…

Malemedicine.medical_specialtyGenotype[SDV]Life Sciences [q-bio]Human immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeAntiviral AgentsGastroenterologychemistry.chemical_compoundPharmacotherapyGene FrequencyRisk FactorsInternal medicineRibavirinmedicineHumansGenetic Predisposition to DiseasePharmacology (medical)PyrophosphatasesAllelesComputingMilieux_MISCELLANEOUSPharmacologyCoinfectionbusiness.industryRibavirinAnemiaHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseFirst generation3. Good health[SDV] Life Sciences [q-bio]Infectious DiseaseschemistryMutationCoinfectionDrug Therapy CombinationFemaleITPAbusinessMetabolism Inborn ErrorsINOSINE TRIPHOSPHATASE
researchProduct

[Contraception in chronically ill adolescents].

2003

Contraception in chronically ill adolescents has to consider side effects with regard to metabolic or hematological disease. Additionally the compliance of the patient has to be taken in account when consulting about contraceptives. In juvenile diabetics with good glycemic control and metabolic diseases of the amino acids oral contraceptives are justifiable. Adolescents with galactose-mia mostly suffer from premature ovarian failure and therefore have to be controlled wether they need contraception at all. Young women with sickle-cell anemia are at risk of thrombophilia. They should not be given hormonal contraceptives. In v. Willebrand-Jurgens-Syndrome oral contraceptives are favourable be…

Malemedicine.medical_specialtyPediatricsAdolescentAnemiaSexual BehaviorDiseaseThrombophiliaDiabetes mellitusmedicineHumansGlycemicGynecologybusiness.industryContraindicationsObstetrics and Gynecologymedicine.diseasePremature ovarian failureChronic diseaseContraceptionDiabetes Mellitus Type 1Sexual behaviorChronic DiseaseFemalebusinessSexualityContraceptives OralZentralblatt fur Gynakologie
researchProduct

Epistaxis and systemic disease

2008

Abstract We report the case of a 77-year-old man who presented nasal obstruction sensation and epistaxis. Otorhinolaryngologic examination revealed occupation of the left nasal passage and the left maxillary sinus by an inflammatory tumour, the biopsy results of which were inconclusive. While diagnostic tests were being carried out, the patient presented a severe systemic condition consisting mainly of anemia, acute renal failure, and cavitated diffuse bilateral lung infiltrates. In the light of the results of anti-neutrophilic cytoplasmic antibodies and renal biopsy, Wegener's granulomatosis was diagnosed and treatment for the disease was instituted, with a favourable response. Finally, cl…

Malemedicine.medical_specialtySystemic diseaseMaxillary Sinus NeoplasmsAnemiaBiopsyComorbidityDiseaseRenal DialysisTrimethoprim Sulfamethoxazole Drug CombinationBiopsyHumansMedicineCyclophosphamideGlucocorticoidsAgedNasal passagesLungPapillomamedicine.diagnostic_testGlomerulosclerosis Focal Segmentalbusiness.industryGranulomatosis with PolyangiitisAnemiaGeneral MedicineAcute Kidney Injurymedicine.diseaseLeft maxillary sinusDermatologySurgeryEpistaxismedicine.anatomical_structureRenal biopsyNasal ObstructionLung Diseases InterstitialTomography X-Ray ComputedbusinessActa Otorrinolaringologica (English Edition)
researchProduct

Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome

2022

[Objective] To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment.

Maleprogressive multifocal leukoencepdiarrheacholinergic receptorplasma exchangemiddle agedadultimmunologic factornauseaanemiahypertrichosisageddrug withdrawaldiabetes mellitusdisease severityTRIALsafetycorticosteroidhypertensionImmunologyMiastenia gravismethotrexateArticlebulbar paralysispancytopeniaMuscular DiseasescompulsionMyasthenia Gravischolinesterase inhibitorcross-sectional studyHumansImmunologic FactorshumanRITUXIMABarthralgiaNeurologíaMalalties muscularsAgedRetrospective Studiesmyasthenia gravisleukopeniaabdominal painDrug testingmajor clinical studyCross-Sectional StudiesDrug side effectscyclophosphamideobservational studyNeurology (clinical)immunoglobulinFEATURESefficacyclinical outcomeelectrophysiological procedurescomputer assisted tomographyDOUBLE-BLINDTratamiento médicorituximabOutcome Assessment Health CareImmunologiamuscle specific tyrosine kinaseRegistriestacrolimusazathioprineMedicamentoGeneral Neurosciencenephrotoxicitygeneral condition deteriorationhyperplasiatrialMiddle Agedliver toxicitydrug toxicityunclassified drugfemaleEfectes secundaris dels medicamentsSAFETYFemaledouble-blindheadacheblindnessAdultAssaigs clínics de medicamentsmalefeaturesfollow uppneumoniacyclosporinemycophenolate mofetilprotein tyrosine kinaseimmunosuppressive agentallergyalopeciaEFFICACYclinical featureosteopeniaSpainprednisonehyperglycemiaautoantibodyFollow-Up Studies
researchProduct

Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A…

2013

International audience; Background & AimsTreatment of hepatitis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to anemia, which has been managed by reducing ribavirin dose and/or erythropoietin therapy. We assessed the effects of these anemia management strategies on rates of sustained virologic response (SVR) and safety.MethodsPatients (n = 687) received 4 weeks of peginterferon and ribavirin followed by 24 or 44 weeks of boceprevir (800 mg, 3 times each day) plus peginterferon and ribavirin. Patients who became anemic (levels of hemoglobin approximately ≤10 g/dL) during the study treatment period (n = 500) were assigned to groups that were managed by ribavi…

Maleviruses[SDV]Life Sciences [q-bio]Hepacivirusmedicine.disease_causeGastroenterologyPolyethylene Glycolslaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawErythropoiesisIncidenceGastroenterologyDisease Managementvirus diseasesAnemiaMiddle AgedRecombinant Proteins3. Good healthTreatment Outcome030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyAlgorithmsmedicine.drugmedicine.medical_specialtyGenotypeProlineSide effectAnemiaHepatitis C virusInterferon alpha-2Antiviral Agents03 medical and health sciencesInternal medicineBoceprevirRibavirinmedicineHumansErythropoietinDAADose-Response Relationship DrugHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicbiochemical phenomena metabolism and nutritionmedicine.diseasedigestive system diseasesSide EffectLogistic ModelschemistryErythropoietinImmunologyHemoglobinbusinessEPO
researchProduct

Hemolytic uremic syndrome in an infant following Bordetella pertussis infection.

2006

Reported here is the case of a 6-week-old female infant with a severe Bordetella pertussis infection requiring supportive pressure-positive ventilation in the intensive care unit. After being discharged from the intensive care unit, she developed hemolytic anemia, thrombocytopenia and acute renal failure, which suggested a diagnosis of hemolytic uremic syndrome. The clinical outcome was favorable with no renal consequences. This case suggests there may be a direct cause-effect relationship between B. pertussis infection and hemolytic uremic syndrome.

Microbiology (medical)Hemolytic anemiaPediatricsmedicine.medical_specialtyBordetella pertussisWhooping CoughPertussis toxinBordetella pertussislaw.inventionMedical microbiologylawmedicineHumansbiologybusiness.industryInfantGeneral Medicinebiology.organism_classificationmedicine.diseaseIntensive care unitInfectious DiseasesHemolytic-Uremic SyndromeImmunologyParoxysmal coughFemalebusinessKidney disease
researchProduct

Acute Parvovirus B19 Infection and Anemia duringPlasmodium falciparumMalaria

2002

Microbiology (medical)Infectious DiseasesbiologyParvovirusbusiness.industryAnemiamedicinePlasmodium falciparummedicine.diseasebiology.organism_classificationbusinessVirologyMalariaClinical Infectious Diseases
researchProduct

Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases

2002

The clinical and epidemiological characteristics of 111 consecutive cases of visceral leishmaniasis identified from 1980 to 2000 in a Sicilian pediatric hospital were analyzed retrospectively. The mean age of the patients was 1.7 years. All children were HIV negative, but 15% were severely malnourished. Fever and splenomegaly were present in all cases and hepatomegaly in 101 (90.1%) cases. Thrombocytopenia and anemia were both observed in 78 (70.2%) cases and leukopenia in 47 (42.3%) cases. A bone marrow aspirate was obtained in all cases; Leishmania amastigotes were detected in 89 (80.2%) cases. Initial treatment consisted of meglumine antimoniate in 99 (89.2%) patients and amphotericin B …

Microbiology (medical)medicine.medical_specialtyAnemiaMeglumine antimoniateAntiprotozoal Agentschildren leishmaniosisMeglumineRecurrenceAmphotericin BAmphotericin BInternal medicineEpidemiologyOrganometallic CompoundsmedicineAnimalsHumansChildSicilyRetrospective StudiesLeishmaniaMeglumine AntimoniateLeukopeniabusiness.industryInfantRetrospective cohort studyLeishmaniasisGeneral Medicinemedicine.diseaseNutrition DisordersSurgeryTreatment OutcomeInfectious DiseasesVisceral leishmaniasisChild PreschoolLeishmaniasis Visceralmedicine.symptombusinessmedicine.drug
researchProduct

Visceral leishmaniasis, hypertriglyceridemia and secondary hemophagocytic lymphohistiocytosis

2016

cytokines, an upregulation of adhesion molecules and MHC I and II molecules on mono/macrophages, and an expansion of inflammatory monocytes. This exaggerated inflammatory response is responsible for necrosis and organ failure and results in uncontrolled proliferation and phagocytic activity of histiocytes [2]. Hypertriglyceridemia (fasting, greater than or equal to 265 mg/100 ml) is one of the current diagnostic criteria for HLH [2]. Several studies link hypertriglyceridemia to inhibition of lipoprotein lipase (LPL) by tumor necrosis factor-α (TNF-α), and TNF-α is a powerful autocrine and paracrine regulator of adipose tissue [3]. Indeed, many different sources of intense and prolonged T-ly…

Microbiology (medical); Infectious Diseases0301 basic medicineMicrobiology (medical)Secondary Hemophagocytic LymphohistiocytosisNecrosisSettore MED/17 - Malattie Infettive030106 microbiologyAdipose tissueTriglycerideSeverityLymphohistiocytosis Hemophagocytic03 medical and health sciences0302 clinical medicinemedicineHumansMacrophage030212 general & internal medicineVisceral leishmaniasisHypertriglyceridemiaLipoprotein lipasebusiness.industryAnemia; Severity; Triglyceride; Visceral leishmaniasisHypertriglyceridemiaAnemiaGeneral Medicinemedicine.diseaseInfectious DiseasesVisceral leishmaniasisImmunologyLeishmaniasis VisceralTumor necrosis factor alphamedicine.symptombusinessInfection
researchProduct